{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:01:59Z","timestamp":1793174519181,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82501892"],"award-info":[{"award-number":["82501892"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171198"],"award-info":[{"award-number":["82171198"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013102","name":"Shanghai Municipal Youth Science and Technology Star Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Western Pacific"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.lanwpc.2026.101817","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T10:25:39Z","timestamp":1771583139000},"page":"101817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Associations of plasma GFAP and P-tau217 with imaging ATN markers and cognitive decline across Centiloid scales"],"prefix":"10.1016","volume":"68","author":[{"given":"Lin","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu-Chung","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9425-6618","authenticated-orcid":false,"given":"Qi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3001-7965","authenticated-orcid":false,"given":"Yi-Hui","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Hao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Feng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.lanwpc.2026.101817_bib1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: an update on pathobiology and treatment strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.lanwpc.2026.101817_bib2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41583-018-0067-3","article-title":"Imaging the evolution and pathophysiology of Alzheimer disease","volume":"19","author":"Jagust","year":"2018","journal-title":"Nat Rev Neurosci"},{"issue":"7","key":"10.1016\/j.lanwpc.2026.101817_bib3","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1148\/rg.2018180160","article-title":"Signs and artifacts in amyloid PET","volume":"38","author":"Lundeen","year":"2018","journal-title":"Radiographics"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101817_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101817_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.lanwpc.2026.101817_bib6","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.lanwpc.2026.101817_bib7","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1002\/alz.14336","article-title":"Centiloid recommendations for clinical context-of-use from the AMYPAD consortium","volume":"20","author":"Collij","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.lanwpc.2026.101817_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2025.103765","article-title":"A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research","volume":"46","author":"Iaccarino","year":"2025","journal-title":"Neuroimage Clin"},{"issue":"12","key":"10.1016\/j.lanwpc.2026.101817_bib9","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer's association appropriate use recommendations for blood biomarkers in Alzheimer's disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101817_bib10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer's disease: towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.lanwpc.2026.101817_bib11","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.lanwpc.2026.101817_bib12","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.lanwpc.2026.101817_bib13","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum","volume":"78","author":"Benedet","year":"2021","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.lanwpc.2026.101817_bib14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","article-title":"Associations of plasma Phospho-Tau217 levels with Tau positron emission tomography in early Alzheimer disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.lanwpc.2026.101817_bib15","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114022","article-title":"Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau","volume":"13","author":"Mattsson-Carlgren","year":"2021","journal-title":"EMBO Mol Med"},{"issue":"7","key":"10.1016\/j.lanwpc.2026.101817_bib16","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/s41591-023-02380-x","article-title":"Astrocyte reactivity influences amyloid-beta effects on tau pathology in preclinical Alzheimer's disease","volume":"29","author":"Bellaver","year":"2023","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.lanwpc.2026.101817_bib17","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213438","article-title":"Association of plasma biomarkers with longitudinal atrophy and microvascular burden on MRI across neurodegenerative and cerebrovascular diseases","volume":"104","author":"Sanchez","year":"2025","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.lanwpc.2026.101817_bib18","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1002\/alz.13560","article-title":"Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: results from the Ontario Neurodegenerative Disease Research Initiative","volume":"20","author":"Sanchez","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101817_bib19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12916-024-03418-8","article-title":"Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank","volume":"22","author":"Wang","year":"2024","journal-title":"BMC Med"},{"issue":"5","key":"10.1016\/j.lanwpc.2026.101817_bib20","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s43587-025-00835-z","article-title":"Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials","volume":"5","author":"Ossenkoppele","year":"2025","journal-title":"Nat Aging"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101817_bib21","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","article-title":"Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers","volume":"80","author":"Mattsson-Carlgren","year":"2023","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.lanwpc.2026.101817_bib22","doi-asserted-by":"crossref","first-page":"571","DOI":"10.14283\/jpad.2023.49","article-title":"Chinese preclinical Alzheimer's disease study (C-PAS): design and challenge from PET acceptance","volume":"10","author":"Cui","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101817_bib23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3233\/JAD-140276","article-title":"Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates","volume":"42","author":"Bondi","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.lanwpc.2026.101817_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"7","key":"10.1016\/j.lanwpc.2026.101817_bib25","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00406-019-01083-0","article-title":"Changes in brain glucose metabolism and connectivity in somatoform disorders: an (18)F-FDG PET study","volume":"270","author":"Huang","year":"2020","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"9","key":"10.1016\/j.lanwpc.2026.101817_bib26","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","article-title":"Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes","volume":"78","author":"Mielke","year":"2021","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.lanwpc.2026.101817_bib27","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","article-title":"Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography","volume":"80","author":"Therriault","year":"2023","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101817_bib28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s43587-023-00380-7","article-title":"CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's disease","volume":"3","author":"Barthelemy","year":"2023","journal-title":"Nat Aging"},{"issue":"10","key":"10.1016\/j.lanwpc.2026.101817_bib29","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1002\/alz.13393","article-title":"Plasma p-tau231 and p-tau217 inform on tau tangles aggregation in cognitively impaired individuals","volume":"19","author":"Ferreira","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"7","key":"10.1016\/j.lanwpc.2026.101817_bib30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology\u2013recommendations from the Global CEO Initiative on Alzheimer's disease","volume":"20","author":"Schindler","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"10.1016\/j.lanwpc.2026.101817_bib31","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/jamaneurol.2022.3157","article-title":"Racial and ethnic differences in amyloid PET positivity in individuals with mild cognitive impairment or dementia: a secondary analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) cohort Study","volume":"79","author":"Wilkins","year":"2022","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.lanwpc.2026.101817_bib32","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.1002\/alz.14247","article-title":"Ethnic differences in the prevalence of amyloid positivity and cognitive trajectories","volume":"20","author":"Jang","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"12","key":"10.1016\/j.lanwpc.2026.101817_bib33","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.lanwpc.2026.101817_bib34","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.lanwpc.2026.101817_bib35","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1002\/alz.14084","article-title":"Correlations between plasma markers and brain Abeta deposition across the AD continuum: evidence from SILCODE","volume":"20","author":"Yu","year":"2024","journal-title":"Alzheimers Dement"}],"container-title":["The Lancet Regional Health - Western Pacific"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606526000210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606526000210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:31:16Z","timestamp":1784579476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666606526000210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"alternative-id":["S2666606526000210"],"URL":"https:\/\/doi.org\/10.1016\/j.lanwpc.2026.101817","relation":{},"ISSN":["2666-6065"],"issn-type":[{"value":"2666-6065","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations of plasma GFAP and P-tau217 with imaging ATN markers and cognitive decline across Centiloid scales","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Western Pacific","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2026.101817","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101817"}}